Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
28.55
-0.36 (-1.25%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Lakefront Biotherapeutics NV Employees
Lakefront Biotherapeutics NV had 196 employees as of June 30, 2026. The number of employees decreased by 256 or -56.64% since the number was reported on December 31, 2025.
Employees
196
Change
-256
Growth
-56.64%
Revenue / Employee
$5,773,962
Profits / Employee
$3,477,735
Market Cap
1.86B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 196 | -256 | -56.64% |
| Dec 31, 2025 | 452 | -252 | -35.80% |
| Dec 31, 2024 | 704 | -419 | -37.31% |
| Dec 31, 2023 | 1,123 | -215 | -16.07% |
| Dec 31, 2022 | 1,338 | 29 | 2.22% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Recursion Pharmaceuticals | 600 |
| Maravai LifeSciences Holdings | 415 |
| Vir Biotechnology | 367 |
| Xencor | 260 |
| Stoke Therapeutics | 170 |
| Septerna | 123 |
| Mesoblast | 108 |
LKFT News
- 4 days ago - Lakefront Biotherapeutics NV Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 days ago - Acquisition of Own Shares - GlobeNewsWire
- 12 days ago - Acquisition of Own Shares - GlobeNewsWire
- 12 days ago - Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 19 days ago - Acquisition of Own Shares - GlobeNewsWire
- 27 days ago - Lakefront Biotherapeutics granted orphan drug designation for gamgertamig - TheFly
- 27 days ago - U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus - GlobeNewsWire
- 27 days ago - Lakefront Receives Transparency Notification from Bank of America - GlobeNewsWire